ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 242 filers reported holding ACCELERON PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $68,778,000 | +31.9% | 399,640 | -3.8% | 0.03% | +30.0% |
| Q2 2021 | $52,125,000 | -5.7% | 415,370 | +1.9% | 0.02% | -9.1% |
| Q1 2021 | $55,292,000 | +12.9% | 407,732 | +6.6% | 0.02% | +4.8% |
| Q4 2020 | $48,956,000 | +13.7% | 382,644 | +0.0% | 0.02% | 0.0% |
| Q3 2020 | $43,044,000 | +214.4% | 382,512 | +10.4% | 0.02% | +200.0% |
| Q3 2019 | $13,689,000 | -3.8% | 346,477 | 0.0% | 0.01% | -12.5% |
| Q2 2019 | $14,233,000 | -53.1% | 346,477 | -46.8% | 0.01% | -50.0% |
| Q1 2019 | $30,335,000 | +28.4% | 651,377 | +20.1% | 0.02% | +14.3% |
| Q4 2018 | $23,628,000 | -5.2% | 542,539 | +24.6% | 0.01% | +16.7% |
| Q3 2018 | $24,928,000 | +18.0% | 435,577 | 0.0% | 0.01% | +9.1% |
| Q2 2018 | $21,134,000 | +24.1% | 435,577 | 0.0% | 0.01% | +22.2% |
| Q1 2018 | $17,031,000 | -7.9% | 435,577 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $18,486,000 | +7.0% | 435,577 | -5.9% | 0.01% | +12.5% |
| Q3 2017 | $17,278,000 | +22.8% | 462,977 | 0.0% | 0.01% | +14.3% |
| Q2 2017 | $14,070,000 | +10.1% | 462,977 | -4.1% | 0.01% | +16.7% |
| Q1 2017 | $12,784,000 | +3.7% | 482,977 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $12,326,000 | -31.2% | 482,977 | -2.4% | 0.01% | -33.3% |
| Q3 2016 | $17,906,000 | +6.5% | 494,777 | 0.0% | 0.01% | 0.0% |
| Q2 2016 | $16,813,000 | +28.8% | 494,777 | 0.0% | 0.01% | +28.6% |
| Q1 2016 | $13,057,000 | -45.9% | 494,777 | -0.1% | 0.01% | -41.7% |
| Q4 2015 | $24,146,000 | +83.7% | 495,200 | -6.2% | 0.01% | +100.0% |
| Q3 2015 | $13,144,000 | -22.3% | 527,877 | -1.3% | 0.01% | -25.0% |
| Q2 2015 | $16,914,000 | -15.2% | 534,577 | +2.0% | 0.01% | -11.1% |
| Q1 2015 | $19,954,000 | -2.3% | 524,277 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $20,426,000 | +24.0% | 524,277 | -3.7% | 0.01% | +12.5% |
| Q3 2014 | $16,468,000 | -26.3% | 544,577 | -17.2% | 0.01% | -20.0% |
| Q2 2014 | $22,331,000 | -11.2% | 657,377 | -9.8% | 0.01% | -16.7% |
| Q1 2014 | $25,136,000 | +6.4% | 728,577 | +22.1% | 0.01% | 0.0% |
| Q4 2013 | $23,624,000 | – | 596,577 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |